Pegah Poursharifi
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Pegah Poursharifi has a total of 135 co-authors. Here are the top co-authors by number of shared publications:
- Marc Prentki
Montreal Diabetes Research Center - Centre de Recherche du Centre Hospitalier de l'Université de Montréal, Montréal, Canada
12 shared publications - Marc Lapointe
Centre de Recherche Institut Universitaire de Cardiologie & Pneumologie de Québec, Université Laval, Québec, Canada
8 shared publications - Sri Ramachandra Murthy Madiraju
Departments of Nutrition, Biochemistry and Molecular Medicine, University of Montreal, and Montreal Diabetes Research Center, Centre de Recherche du Centre Hospitalier de l'Université de Montréal (CRCHUM), Montréal, QC, Canada
8 shared publications - Katherine Cianflone
Centre de Recherche Institut Universitaire de Cardiologie & Pneumologie de Québec, Université Laval, Québec, Canada
7 shared publications Marie-Line Peyot
Montreal Diabetes Research Center - Centre de Recherche du Centre Hospitalier de l'Université de Montréal, and departments of Nutrition and Biochemistry, University of Montreal, Montreal, Canada
6 shared publicationsAbhishek Gupta
Centre de Recherche Institut Universitaire de Cardiologie & Pneumologie de Québec Université Laval Québec City QC Canada
5 shared publications
Latest Publications
- Open Access
- 6 October 2025
- Published by Elsevier in Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids
- Vol. 1871 (1) , 159694
ABHD6 suppression attenuates pro-inflammatory responses in mice and promotes anti-inflammatory polarization of macrophages during endotoxin stress
- 6 October 2025
- Published by Elsevier in Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids
- Vol. 1871 (1) , 159694
Open AccessABHD6 suppression attenuates pro-inflammatory responses in mice and promotes anti-inflammatory polarization of macrophages during endotoxin stress
- Top Cited Papers
- 1 October 2025
- Published by American Physiological Society in Physiological Reviews
- Vol. 105 (4) , 2449-2499
Glycerolipid Cycling in Thermogenesis, Energy Homeostasis, Signaling, and Diseases
Mammals maintain body heat by adaptive energy expenditure through different organ-specific mechanisms. The glycerolipid/free fatty acid (FFA) cycle (glycerolipid cycle), encompassing triglyceride lipolysis and FFA release followed by their reesterification, is an ATP-consuming process that contributes to energy expenditure, heat production, and various lipid signaling pathways. The glycerolipid cycle, which was originally described as a whole body process, is now known to also occur intracellularly in many organs. This review focuses on the thermogenic and signaling roles of glycerolipid cycling in adipose and other tissues and offers insight into the various pathophysiological conditions where its activity is altered. We discuss its substrates and products, enzyme components, and regulation. We present evidence that this cycling process, besides acting as the complete triglyceride/FFA cycle, is in fact composed of multiple shorter subcycles, which can be activated individually. We highlight the importance of this energy-dissipating cycle in adaptive thermogenesis and energy expenditure in animals and humans and discuss the latest methodological advances to quantify its flux. The much renewed interest in this area has begun to showcase the central role of glycerolipid cycling mediated thermogenesis and signaling in cardiometabolic diseases, cancer, and aging that could be harnessed for therapy.
- 1 October 2025
- Published by American Physiological Society in Physiological Reviews
- Vol. 105 (4) , 2449-2499
Top Cited PapersGlycerolipid Cycling in Thermogenesis, Energy Homeostasis, Signaling, and Diseases
Mammals maintain body heat by adaptive energy expenditure through different organ-specific mechanisms. The glycerolipid/free fatty acid (FFA) cycle (glycerolipid cycle), encompassing triglyceride lipolysis and FFA release followed by their reesterification, is an ATP-consuming process that contributes to energy expenditure, heat production, and various lipid signaling pathways. The glycerolipid cycle, which was originally described as a whole body process, is now known to also occur intracellularly in many organs. This review focuses on the thermogenic and signaling roles of glycerolipid cycling in adipose and other tissues and offers insight into the various pathophysiological conditions where its activity is altered. We discuss its substrates and products, enzyme components, and regulation. We present evidence that this cycling process, besides acting as the complete triglyceride/FFA cycle, is in fact composed of multiple shorter subcycles, which can be activated individually. We highlight the importance of this energy-dissipating cycle in adaptive thermogenesis and energy expenditure in animals and humans and discuss the latest methodological advances to quantify its flux. The much renewed interest in this area has begun to showcase the central role of glycerolipid cycling mediated thermogenesis and signaling in cardiometabolic diseases, cancer, and aging that could be harnessed for therapy.
- Open Access
- 29 August 2025
- Published by Elsevier in Molecular Metabolism
- Vol. 101, 102241
Suppression of adipocyte ABHD6 favors anti-inflammatory and adipogenic programs to preserve adipose tissue fitness in obesity
- 29 August 2025
- Published by Elsevier in Molecular Metabolism
- Vol. 101, 102241
Open AccessSuppression of adipocyte ABHD6 favors anti-inflammatory and adipogenic programs to preserve adipose tissue fitness in obesity
- Open Access
- 12 October 2023
- Published by Elsevier in Molecular Metabolism
- Vol. 78, 101822
ABHD6 suppression promotes anti-inflammatory polarization of adipose tissue macrophages via 2-monoacylglycerol/PPAR signaling in obese mice
- 12 October 2023
- Published by Elsevier in Molecular Metabolism
- Vol. 78, 101822
Open AccessABHD6 suppression promotes anti-inflammatory polarization of adipose tissue macrophages via 2-monoacylglycerol/PPAR signaling in obese mice
- 1 November 2021
- Published by Elsevier in Canadian Journal of Diabetes
- Vol. 45 (7) , S8
Suppression of ABHD6 Promotes Healthy Expansion of Adipose Tissue in Obesity
- 1 November 2021
- Published by Elsevier in Canadian Journal of Diabetes
- Vol. 45 (7) , S8
Suppression of ABHD6 Promotes Healthy Expansion of Adipose Tissue in Obesity
- Open Access
- 14 May 2021
- Published by Wiley in The FASEB Journal
- Vol. 35 (S1)
Suppression of ABHD6 Promotes Healthy Expansion of Adipose Tissue in Obesity
The mode of white adipose tissue (WAT) expansion in response to positive energy balance greatly impacts obesity‐related metabolic abnormalities. Pathologic WAT remodeling, characterized by adipocyte hypertrophy and reduced differentiation capacity, results in chronic inflammation, ectopic fat accumulation and insulin resistance. Conversely, healthy adipogenesis is characterized by adipocyte hyperplasia, reduced inflammation and limited fat spill‐over in other organs. Pan‐deletion of the monoacylglycerol lipase alpha/beta hydrolase domain‐6 (ABHD6) demonstrated the therapeutic potential of ABHD6 inhibitors against obesity and type‐2‐diabetes. However, the role of ABHD6 in diet‐induced adipogenesis and adipose inflammation remains unexplored. Here we present evidence, employing pharmacological and genetic approaches, that ABHD6 suppression maintains AT immunometabolic health during high fat diet (HFD)‐induced obesity. ABHD6 expression increases in mouse adipocytes during differentiation, and correlates with the adiposity in WAT of HFD‐fed mice and in visceral fat of patients with obesity. Treatment of adipocytes with the ABHD6 inhibitor (KT203) prior to induction of differentiation increases the expression of adipogenic markers and the number of smaller lipid droplets. In addition, ABHD6 deletion in mice enhances differentiation capacity of primary inguinal pre‐adipocytes. HFD‐fed whole‐body ABHD6‐KO mice exhibit lower expression of proinflammatory cytokines, and less fibrosis and hypoxia parameters in all fat depots. Proinflammatory M1 macrophages in the visceral and brown fat depots are also reduced in HFD‐fed KO mice. Furthermore, the stromal vascular fraction from WAT of HFD‐fed KO mice display reduced glycolytic and increased oxidative rates. Interestingly, other tissues of KO mice, including liver, heart and spleen, show reduced weight, decreased proinflammatory markers and lower fat content, compared to wild type mice on HFD. The results suggest that inhibition/deletion of ABHD6 in HFD fed mice enhances AT capacity to recruit new fat cells through differentiation of pre‐adipocytes, reduces lipid spill‐over in other organs and ameliorates inflammation. These findings provide insight into the role of ABHD6 in the immunometabolic pathways during WAT expansion, and suggest ABHD6 as a therapeutic target for inflammation and obesity‐related complications.
- 14 May 2021
- Published by Wiley in The FASEB Journal
- Vol. 35 (S1)
Open AccessSuppression of ABHD6 Promotes Healthy Expansion of Adipose Tissue in Obesity
The mode of white adipose tissue (WAT) expansion in response to positive energy balance greatly impacts obesity‐related metabolic abnormalities. Pathologic WAT remodeling, characterized by adipocyte hypertrophy and reduced differentiation capacity, results in chronic inflammation, ectopic fat accumulation and insulin resistance. Conversely, healthy adipogenesis is characterized by adipocyte hyperplasia, reduced inflammation and limited fat spill‐over in other organs. Pan‐deletion of the monoacylglycerol lipase alpha/beta hydrolase domain‐6 (ABHD6) demonstrated the therapeutic potential of ABHD6 inhibitors against obesity and type‐2‐diabetes. However, the role of ABHD6 in diet‐induced adipogenesis and adipose inflammation remains unexplored. Here we present evidence, employing pharmacological and genetic approaches, that ABHD6 suppression maintains AT immunometabolic health during high fat diet (HFD)‐induced obesity. ABHD6 expression increases in mouse adipocytes during differentiation, and correlates with the adiposity in WAT of HFD‐fed mice and in visceral fat of patients with obesity. Treatment of adipocytes with the ABHD6 inhibitor (KT203) prior to induction of differentiation increases the expression of adipogenic markers and the number of smaller lipid droplets. In addition, ABHD6 deletion in mice enhances differentiation capacity of primary inguinal pre‐adipocytes. HFD‐fed whole‐body ABHD6‐KO mice exhibit lower expression of proinflammatory cytokines, and less fibrosis and hypoxia parameters in all fat depots. Proinflammatory M1 macrophages in the visceral and brown fat depots are also reduced in HFD‐fed KO mice. Furthermore, the stromal vascular fraction from WAT of HFD‐fed KO mice display reduced glycolytic and increased oxidative rates. Interestingly, other tissues of KO mice, including liver, heart and spleen, show reduced weight, decreased proinflammatory markers and lower fat content, compared to wild type mice on HFD. The results suggest that inhibition/deletion of ABHD6 in HFD fed mice enhances AT capacity to recruit new fat cells through differentiation of pre‐adipocytes, reduces lipid spill‐over in other organs and ameliorates inflammation. These findings provide insight into the role of ABHD6 in the immunometabolic pathways during WAT expansion, and suggest ABHD6 as a therapeutic target for inflammation and obesity‐related complications.
- Open Access
- 17 December 2020
- Published by American Society for Clinical Investigation in JCI Insight
- Vol. 5 (24)
Adipose ABHD6 regulates tolerance to cold and thermogenic programs
Enhanced energy expenditure in brown (BAT) and white adipose tissues (WAT) can be therapeutic against metabolic diseases. We examined the thermogenic role of adipose α/β-hydrolase domain 6 (ABHD6), which hydrolyzes monoacylglycerol (MAG), by employing adipose-specific ABHD6-KO mice. Control and KO mice showed similar phenotypes at room temperature and thermoneutral conditions. However, KO mice were resistant to hypothermia, which can be accounted for by the simultaneously increased lipolysis and lipogenesis of the thermogenic glycerolipid/free fatty acid (GL/FFA) cycle in visceral fat, despite unaltered uncoupling protein 1 expression. Upon cold stress, nuclear 2-MAG levels increased in visceral WAT of the KO mice. Evidence is provided that 2-MAG causes activation of PPARα in white adipocytes, leading to elevated expression and activity of GL/FFA cycle enzymes. In the ABHD6-ablated BAT, glucose and oxidative metabolism were elevated upon cold induction, without changes in GL/FFA cycle and lipid turnover. Moreover, response to in vivo β 3 -adrenergic stimulation was comparable between KO and control mice. Our data reveal a MAG/PPARα/GL/FFA cycling metabolic signaling network in visceral adipose tissue, which contributes to cold tolerance, and that adipose ABHD6 is a negative modulator of adaptive thermogenesis.
- 17 December 2020
- Published by American Society for Clinical Investigation in JCI Insight
- Vol. 5 (24)
Open AccessAdipose ABHD6 regulates tolerance to cold and thermogenic programs
Enhanced energy expenditure in brown (BAT) and white adipose tissues (WAT) can be therapeutic against metabolic diseases. We examined the thermogenic role of adipose α/β-hydrolase domain 6 (ABHD6), which hydrolyzes monoacylglycerol (MAG), by employing adipose-specific ABHD6-KO mice. Control and KO mice showed similar phenotypes at room temperature and thermoneutral conditions. However, KO mice were resistant to hypothermia, which can be accounted for by the simultaneously increased lipolysis and lipogenesis of the thermogenic glycerolipid/free fatty acid (GL/FFA) cycle in visceral fat, despite unaltered uncoupling protein 1 expression. Upon cold stress, nuclear 2-MAG levels increased in visceral WAT of the KO mice. Evidence is provided that 2-MAG causes activation of PPARα in white adipocytes, leading to elevated expression and activity of GL/FFA cycle enzymes. In the ABHD6-ablated BAT, glucose and oxidative metabolism were elevated upon cold induction, without changes in GL/FFA cycle and lipid turnover. Moreover, response to in vivo β 3 -adrenergic stimulation was comparable between KO and control mice. Our data reveal a MAG/PPARα/GL/FFA cycling metabolic signaling network in visceral adipose tissue, which contributes to cold tolerance, and that adipose ABHD6 is a negative modulator of adaptive thermogenesis.
- 7 September 2017
- Published by Wiley in Diabetes, Obesity and Metabolism
- Vol. 19 (S1) , 76-89
Monoacylglycerol signalling and ABHD6 in health and disease
Lipid metabolism dysregulation underlies chronic pathologies such as obesity, diabetes and cancer. Besides their role in structure and energy storage, lipids are also important signalling molecules regulating multiple biological functions. Thus, understanding the precise lipid metabolism enzymatic steps that are altered in some pathological conditions is helpful for designing better treatment strategies. Several monoacylglycerol (MAG) species are only recently being recognized as signalling lipid molecules in different tissues. Recent studies indicated the importance of the ubiquitously expressed serine hydrolase α/β‐hydrolase domain 6 (ABHD6), which is a MAG hydrolase, in regulating signalling competent MAG in both central and peripheral tissues. The central and peripheral function of the endocannabinoid 2‐arachidonoylglycerol, which is a 2‐MAG, and its breakdown by both ABHD6 and classical MAG lipase has been well documented. ABHD6 and its substrate MAG appear to be involved in the regulation of various physiological and pathological processes including insulin secretion, adipose browning, food intake, neurotransmission, autoimmune disorders, neurological and metabolic diseases as well as cancer. Diverse cellular targets such as mammalian unc13‐1 (Munc13‐1), PPARs, GPR119 and CB1/2 receptors, for MAG‐mediated signalling processes have been proposed in different cell types. The purpose of this review is to provide a comprehensive summary of the current state of knowledge regarding ABHD6/MAG signalling and its possible therapeutic implications.
- 7 September 2017
- Published by Wiley in Diabetes, Obesity and Metabolism
- Vol. 19 (S1) , 76-89
Monoacylglycerol signalling and ABHD6 in health and disease
Lipid metabolism dysregulation underlies chronic pathologies such as obesity, diabetes and cancer. Besides their role in structure and energy storage, lipids are also important signalling molecules regulating multiple biological functions. Thus, understanding the precise lipid metabolism enzymatic steps that are altered in some pathological conditions is helpful for designing better treatment strategies. Several monoacylglycerol (MAG) species are only recently being recognized as signalling lipid molecules in different tissues. Recent studies indicated the importance of the ubiquitously expressed serine hydrolase α/β‐hydrolase domain 6 (ABHD6), which is a MAG hydrolase, in regulating signalling competent MAG in both central and peripheral tissues. The central and peripheral function of the endocannabinoid 2‐arachidonoylglycerol, which is a 2‐MAG, and its breakdown by both ABHD6 and classical MAG lipase has been well documented. ABHD6 and its substrate MAG appear to be involved in the regulation of various physiological and pathological processes including insulin secretion, adipose browning, food intake, neurotransmission, autoimmune disorders, neurological and metabolic diseases as well as cancer. Diverse cellular targets such as mammalian unc13‐1 (Munc13‐1), PPARs, GPR119 and CB1/2 receptors, for MAG‐mediated signalling processes have been proposed in different cell types. The purpose of this review is to provide a comprehensive summary of the current state of knowledge regarding ABHD6/MAG signalling and its possible therapeutic implications.
- Open Access
- 27 September 2016
- Published by Springer Nature in Diabetologia
- Vol. 59 (12) , 2654-2663
A beta cell ATGL-lipolysis/adipose tissue axis controls energy homeostasis and body weight via insulin secretion in mice
To directly assess the role of beta cell lipolysis in insulin secretion and whole-body energy homeostasis, inducible beta cell-specific adipose triglyceride lipase (ATGL)-deficient (B-Atgl-KO) mice were studied under normal diet (ND) and high-fat diet (HFD) conditions.
- 27 September 2016
- Published by Springer Nature in Diabetologia
- Vol. 59 (12) , 2654-2663
Open AccessA beta cell ATGL-lipolysis/adipose tissue axis controls energy homeostasis and body weight via insulin secretion in mice
To directly assess the role of beta cell lipolysis in insulin secretion and whole-body energy homeostasis, inducible beta cell-specific adipose triglyceride lipase (ATGL)-deficient (B-Atgl-KO) mice were studied under normal diet (ND) and high-fat diet (HFD) conditions.
- Open Access
- 1 March 2016
- Published by Elsevier in Cell Reports
- Vol. 14 (12) , 2872-2888
α/β-Hydrolase Domain 6 Deletion Induces Adipose Browning and Prevents Obesity and Type 2 Diabetes
- 1 March 2016
- Published by Elsevier in Cell Reports
- Vol. 14 (12) , 2872-2888
Open Accessα/β-Hydrolase Domain 6 Deletion Induces Adipose Browning and Prevents Obesity and Type 2 Diabetes